SMILES: CC[C@H](NC(=O)Nc1cc(F)cc(C#N)c1)[C@H](O)c1ccccc1
Response: The pharmacokinetic (PK) properties of the drug CC[C@H](NC(=O)Nc1cc(F)cc(C#N)c1)[C@H](O)c1ccccc1 describe how the body handles the drug in terms of its absorption, distribution, metabolism, and excretion (ADME).

Based on the predictions:

**1. Absorption (A):**
*   **Oral Bioavailability:** The drug is predicted to have **low oral bioavailability (< 20%)**. This suggests that only a small fraction of an orally administered dose would reach systemic circulation.
*   **Aqueous Solubility:** It exhibits **poor aqueous solubility** (logS = -4.9), which is a significant factor contributing to its low bioavailability, as it limits the amount of drug available for absorption.
*   **Membrane Permeability:** **Caco-2 permeability is predicted to be low**, further hindering its passage across the intestinal membrane.
*   **Overall Absorption:** The combination of poor solubility and low permeability, alongside significant first-pass metabolism (discussed below), collectively explains the challenging and low oral absorption.

**2. Distribution (D):**
*   **Molecular Weight (MW):** 367.40 g/mol.
*   **Lipophilicity (LogP):** With a LogP of 4.01, the drug is moderately to highly lipophilic. This characteristic strongly suggests a **high degree of plasma protein binding**, which would limit the concentration of free, active drug available for distribution and target engagement.
*   **Volume of Distribution at Steady State (VDss):** Predicted at **2.41 L/kg**. This moderate volume of distribution indicates that the drug distributes beyond the plasma compartment into various body tissues, suggesting some tissue partitioning but not extremely extensive tissue binding.
*   **Total Polar Surface Area (TPSA):** A TPSA of 95.82 Å² is relatively high, and combined with low Caco-2 permeability, implies restricted permeation across biological membranes.
*   **Blood-Brain Barrier (BBB) Permeation:** Given its high TPSA and low permeability, the drug is **unlikely to readily cross the blood-brain barrier**.

**3. Metabolism (M):**
*   **Primary Metabolic Pathways:** The drug is anticipated to undergo significant oxidative metabolism. Key sites include:
    *   **Hydroxylation at the alpha-carbon** to the phenyl ring bearing the hydroxyl group (`CH-OH`).
    *   **Oxidation (hydroxylation)** of the ethyl chain.
    *   **Hydroxylation** on both the terminal phenyl ring and the fluorophenyl ring.
*   **Major CYP Enzymes Involved:** It is predicted to be a **substrate for both CYP3A4 and CYP2D6**. As CYP3A4 is the most abundant CYP enzyme in the human liver and intestine, its involvement suggests that the drug is likely to undergo **extensive first-pass metabolism**, which further reduces its systemic bioavailability after oral administration. This also indicates a potential for **drug-drug interactions** when co-administered with inhibitors or inducers of these CYP enzymes.

**4. Excretion (E):**
*   **Half-Life:** The predicted half-life of **15.6 hours** indicates a moderate elimination rate from the body. Once absorbed and distributed, the drug persists for a reasonable duration.
*   **Route of Excretion:** Due to significant predicted metabolism by CYP enzymes, the primary route of elimination for the parent drug and its metabolites is expected to be **hepatic clearance**. Metabolites are likely to be primarily excreted via **biliary secretion into the feces**. More polar metabolites, resulting from oxidative modifications and subsequent conjugation (e.g., glucuronidation), might also undergo some renal excretion (via urine). Direct renal excretion of the unchanged parent compound is likely to be limited given its poor aqueous solubility and lipophilicity.

**Overall PK Profile:**
This drug presents a challenging pharmacokinetic profile, primarily characterized by **low oral bioavailability**. This is a critical limitation stemming from a combination of poor aqueous solubility, low membrane permeability, and extensive first-pass metabolism, particularly by CYP3A4. Once in the systemic circulation, it exhibits a moderate volume of distribution and a half-life suitable for typical dosing regimens. However, its significant metabolism and high plasma protein binding will largely dictate its systemic exposure and elimination. These properties suggest that achieving therapeutically effective systemic concentrations via oral administration may be difficult, potentially necessitating alternative routes of administration or advanced formulation strategies to improve its PK profile.
============================================================
SMILES: CN1C(=O)C[C@H](C(=O)Nc2cc(F)cc(C#N)c2)[C@H]1c1cccc(F)c1
Response: The predicted pharmacokinetic (PK) properties for the drug CN1C(=O)C[C@H](C(=O)Nc2cc(F)cc(C#N)c2)[C@H]1c1cccc(F)c1 are:

*   **Oral Bioavailability**: Less than 20%
*   **Half-Life**: 2.00 hours
*   **Steady-State Volume of Distribution (VDss)**: 1.00 L/kg
============================================================
SMILES: CS(=O)(=O)[C@@H]1CCCN(S(=O)(=O)c2cc(F)cc(C#N)c2)CC1
Response: The pharmacokinetic (PK) properties for the drug with the SMILES string CS(=O)(=O)[C@@H]1CCCN(S(=O)(=O)c2cc(F)cc(C#N)c2)CC1 are predicted as follows:

*   **Oral Bioavailability**: The drug is predicted to have low oral bioavailability, specifically less than 20%. This suggests that a significant portion of the orally administered dose may not reach systemic circulation.
*   **Half-Life**: The predicted half-life is approximately 1.00 hour. This indicates that the drug is eliminated from the body relatively quickly.
*   **Steady-State Volume of Distribution (VDss)**: The predicted VDss is very low at 0.00 L/kg. This suggests that the drug is largely confined to the plasma compartment and has very limited distribution into tissues.

Further detailed information regarding its metabolism, specific excretion pathways, or plasma protein binding could not be obtained with the available predictive tools.
============================================================
SMILES: CS(=O)(=O)[C@H]1CCC[C@H](NS(=O)(=O)c2ccc(F)cc2C#N)C1
Response: The pharmacokinetic (PK) properties of the drug CS(=O)(=O)[C@H]1CCC[C@H](NS(=O)(=O)c2ccc(F)cc2C#N)C1 are predicted as follows:

*   **Oral Bioavailability:** This drug is predicted to have oral bioavailability of less than 20%, suggesting poor absorption when administered orally.
*   **Half-life (Obach model):** The predicted half-life is 54.00 hours. This indicates a long duration of action within the body, which could allow for less frequent dosing.
*   **Steady-state Volume of Distribution (VDss, Lombardo method):** The predicted VDss is 1.00 L/kg. A value around 1 L/kg suggests moderate distribution into tissues beyond the plasma, indicating that the drug does not extensively accumulate in or distribute throughout most body tissues.
============================================================
SMILES: CS(=O)(=O)c1cc(Br)cc(C(=O)Nc2cc(F)cc(C#N)c2)c1F
Response: The PK properties of the drug CS(=O)(=O)c1cc(Br)cc(C(=O)Nc2cc(F)cc(C#N)c2)c1F are predicted and inferred as follows:

*   **Absorption:** Oral absorption is predicted to be **low (oral bioavailability < 20%)**. This is likely due to the molecule's relatively high molecular weight (~414 g/mol), substantial lipophilicity, and the presence of multiple polar groups (sulfonamide, amide, nitrile, halogens) which contribute to a potentially high polar surface area and numerous hydrogen bond acceptors/donors. These characteristics may lead to poor aqueous solubility and/or efflux by transporters, limiting its ability to cross biological membranes effectively.
*   **Distribution:** The predicted steady-state volume of distribution (VDss) is **22.00 L/kg**, which is a high value. This, combined with its high lipophilicity (multiple aromatic rings, halogens), suggests **extensive plasma protein binding** and widespread distribution into tissues, consistent with good tissue penetration.
*   **Metabolism:** The molecule contains several functional groups that are common sites for metabolism. The aromatic rings are susceptible to **cytochrome P450 (CYP)-mediated hydroxylation**. The sulfonamide and amide linkages could potentially be targets for hydrolysis, though amide bonds are generally stable. The nitrile group can also be metabolized, for instance, via hydration to an amide or carboxylic acid, or reductive defluorination. The presence of halogens (bromine and fluorine) can influence metabolic stability and pathways.
*   **Elimination/Excretion:** The predicted **long half-life of 203 hours** suggests very slow clearance from the body. Excretion would primarily involve the elimination of metabolites formed during biotransformation. Depending on their polarity, metabolites could be excreted via both **renal (kidney) and biliary (bile/feces) pathways**. Given the predicted low oral absorption and exceptionally long half-life, the drug might accumulate significantly in the body with repeated dosing, warranting careful consideration of dosing frequency and potential for adverse effects from accumulation.
============================================================
SMILES: CS(=O)(=O)c1cc(Br)cc(C(=O)Nc2ccc(F)cc2C#N)c1F
Error: 400 An internal error has occurred. Please retry or report in https://developers.generativeai.google/guide/troubleshooting
============================================================
SMILES: CS(=O)(=O)c1cc(C(=O)Nc2ccc(F)cc2C#N)cc([N+](=O)[O-])c1
Response: The pharmacokinetic (PK) properties of the drug CS(=O)(=O)c1cc(C(=O)Nc2ccc(F)cc2C#N)cc([N+](=O)[O-])c1 are as follows:

*   **Oral Bioavailability:** Predicted to be < 20%.
*   **Half-Life (Obach model):** Predicted to be 33.00 hours.
*   **Steady-State Volume of Distribution (VDss Lombardo model):** Predicted to be 55.00 L/kg.

These predictions suggest the drug may have limited oral absorption, a relatively long half-life, and distributes widely in the body.
============================================================
SMILES: CS(=O)(=O)c1cc(C(=O)Nc2ccc(F)cc2C#N)ccc1Br
Response: Based on the predictions, here are the pharmacokinetic (PK) properties of the drug CS(=O)(=O)c1cc(C(=O)Nc2ccc(F)cc2C#N)ccc1Br:

*   **Oral Bioavailability:** The drug is predicted to have an oral bioavailability of less than 20%. This suggests poor absorption after oral administration.
*   **Half-Life:** The predicted half-life for this drug is 322.00 hours, which is very long. This indicates the drug would stay in the body for an extended period.
*   **Volume of Distribution at Steady State (VDss):** The predicted VDss is 1.00 L/kg. This value suggests that the drug distributes relatively well throughout the body's tissues, but it is not extensively sequestered in tissues as very high VDss values would indicate.
============================================================
SMILES: CS(=O)(=O)c1cc([N+](=O)[O-])ccc1Oc1cc(F)cc([N+](=O)[O-])c1
Response: The predicted pharmacokinetic (PK) properties of the drug with the SMILES string CS(=O)(=O)c1cc([N+](=O)[O-])ccc1Oc1cc(F)cc([N+](=O)[O-])c1 are as follows:

*   **Oral Bioavailability:** The drug is predicted to have oral bioavailability of less than 20%. This suggests that if administered orally, a substantial portion of the drug may not be absorbed into the systemic circulation.
*   **Half-Life (Obach model):** The predicted half-life is 10.00 hours. This indicates that the drug has a moderate duration of presence in the body before being eliminated.
*   **Steady-State Volume of Distribution (VDss, Lombardo method):** The predicted VDss is 0.81 L/kg. This value suggests that the drug distributes moderately into the body's tissues, meaning it is not highly confined to the bloodstream nor extensively accumulated in specific tissues.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@@H](O)C(F)(F)CC2
Response: Based on the predictions performed, the pharmacokinetic (PK) properties of the drug CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@@H](O)C(F)(F)CC2 are as follows:

*   **Oral Bioavailability:** The drug is predicted to have an oral bioavailability of less than 20%. This suggests that only a small fraction of the orally administered dose will reach systemic circulation, potentially due to poor absorption or significant first-pass metabolism.
*   **Half-life:** The predicted half-life of the drug is approximately 11-13 hours (10.99 hours via Obach prediction and 13.00 hours via Lombardo prediction). This indicates a moderately long duration of action, suggesting that dosing might be once or twice daily.
*   **Steady-state Volume of Distribution (VDss):** The predicted VDss is 17.00 L/kg. A high VDss value like this suggests extensive distribution of the drug into tissues outside the plasma compartment.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)CC2(F)F
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)CC2(F)F are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%.
*   **Half-life (Obach model):** Predicted to be 13.00 hours.
*   **Steady-state Volume of Distribution (VDss, Lombardo method):** Predicted to be 3.00 L/kg.

**Interpretation of these PK properties:**

1.  **Low Oral Bioavailability (<20%):** This indicates that only a small fraction of the orally administered drug reaches the systemic circulation unchanged. This could be due to poor absorption from the gastrointestinal tract, extensive first-pass metabolism in the liver or gut wall, or significant efflux by transporters. For therapeutic use, this often implies that an oral formulation might be inefficient, requiring very high doses, or that alternative routes of administration (e.g., intravenous) would be necessary to achieve desired systemic exposure.

2.  **Half-life of 13.00 hours:** A half-life of approximately 13 hours suggests that the drug is eliminated from the body at a moderate rate. This duration typically allows for once or twice-daily dosing regimens to maintain therapeutic concentrations, provided the drug is absorbed consistently and effectively.

3.  **Volume of Distribution (VDss) of 3.00 L/kg:** A VDss of 3.00 L/kg is considered relatively high. This suggests that the drug distributes extensively into tissues outside the vascular compartment, rather than remaining largely confined to the plasma. High VDss can indicate good tissue penetration and potential for accumulation in specific tissues. It also implies that a larger total dose may be required to achieve a desired plasma concentration.

In summary, this drug is predicted to have poor oral absorption, requiring careful consideration of its formulation or route of administration. However, once absorbed, it is expected to have a moderate half-life suitable for convenient dosing and distributes extensively into body tissues.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@H]2F
Response: The PK properties of the drug with SMILES `CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@H]2F` are predicted as follows:

*   **Oral Bioavailability:** Predicted to be **< 20%**, indicating low oral bioavailability, which suggests that a significant portion of the orally administered drug may not reach systemic circulation.
*   **Half-Life:** Predicted to be **1.00 hours** (Obach model), suggesting a relatively short duration of action, meaning it might need frequent dosing if administered.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be **3.00 L/kg** (Lombardo method). This value suggests that the drug distributes moderately into tissues rather than being confined primarily to the bloodstream.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(F)c2)c(S(C)(=O)=O)c1
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug CS(=O)(=O)c1ccc(Oc2cc(F)cc(F)c2)c(S(C)(=O)=O)c1 are as follows:

1.  **Absorption (A):** The drug is predicted to have **poor oral bioavailability, less than 20%**. This suggests that only a small fraction of an orally administered dose would reach systemic circulation. Factors contributing to this low bioavailability could include poor solubility, low permeability across the gastrointestinal tract, or significant first-pass metabolism.
2.  **Distribution (D):** The predicted volume of distribution at steady state (VDss) is **0.00 L/kg**. This remarkably low value suggests that the drug is primarily confined to the plasma compartment and does not extensively distribute into body tissues. This characteristic might be due to high plasma protein binding, high hydrophilicity, or an inability to readily cross cell membranes.
3.  **Metabolism (M) & Excretion (E):** The predicted half-life is **8.00 hours**. This indicates a moderate rate of elimination from the body, implying that the drug is cleared through a combination of metabolism and/or excretion processes over this time frame. Specific metabolic pathways or excretion routes are not predicted by the current data.

In summary, this compound is predicted to face significant challenges with oral absorption and widespread tissue distribution, primarily remaining within the circulatory system, with a moderate half-life for elimination. No existing published research on this specific compound was found.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc([N+](=O)[O-])c2)c([N+](=O)[O-])c1
Response: The pharmacokinetic (PK) properties of the drug with the SMILES string CS(=O)(=O)c1ccc(Oc2cc(F)cc([N+](=O)[O-])c2)c([N+](=O)[O-])c1 are predicted as follows:

*   **Oral Bioavailability:** The drug is predicted to have very poor oral bioavailability, specifically less than 20%. This indicates that a significant portion of the orally administered drug may not reach systemic circulation.
*   **Half-Life:** The predicted half-life is 1.00 hour (Obach model), suggesting rapid elimination from the body.
*   **Volume of Distribution at Steady State (VDss):** The predicted VDss is 0.00 L/kg (Lombardo model), implying very limited distribution into tissues and a tendency to remain primarily in the plasma compartment.

In summary, this drug is characterized by poor oral absorption, rapid clearance, and minimal tissue distribution. These characteristics suggest potential challenges in achieving and maintaining therapeutic concentrations via oral administration.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2ccc(C#N)cc2)c(S(C)(=O)=O)c1
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug CS(=O)(=O)c1ccc(Oc2ccc(C#N)cc2)c(S(C)(=O)(=O)c1 are as follows:

*   **Oral Bioavailability:** The drug is predicted to have very poor oral bioavailability, specifically less than 20%. This suggests that only a small fraction of an orally administered dose would reach systemic circulation.
*   **Half-Life:** It has a predicted half-life of 1.00 hour. This indicates a very short duration of action, meaning the drug would be rapidly eliminated from the body.
*   **Volume of Distribution (VDss):** The predicted steady-state volume of distribution (VDss) is 0.00 L/kg. This extremely low value implies that the drug is largely confined to the plasma and extracellular fluid, with minimal distribution into tissues.

In summary, this drug is predicted to have unfavorable PK properties for oral administration, characterized by poor absorption, rapid elimination, and limited distribution beyond the central compartment.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2ccc(F)cc2)c(S(C)(=O)=O)c1
Response: The predicted pharmacokinetic properties of this drug include an oral bioavailability of less than 20%, indicating poor absorption. Additionally, it is predicted to have a very short half-life of 1.00 hours, suggesting rapid elimination from the body.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cccc(C(N)=O)c2)c(N)c1
Response: Based on the predictions, the PK properties of the drug CS(=O)(=O)c1ccc(Oc2cccc(C(N)=O)c2)c(N)c1 are as follows:

*   **Oral Bioavailability:** The compound is predicted to have low oral bioavailability, estimated to be less than 20%.
*   **Half-Life:** The predicted half-life is approximately 1.00 hour, suggesting a relatively short duration of action.
*   **Volume of Distribution (VDss):** The predicted steady-state volume of distribution is 1.00 L/kg. This value indicates that the drug is distributed beyond the plasma volume, suggesting some tissue distribution, but not extensive.
*   **Existing Literature:** A search for this specific compound in PubMed did not yield any results, suggesting that experimental pharmacokinetic data for this exact molecule might not be readily available in the published literature.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cccc(F)c2)c(S(C)(=O)=O)c1
Response: Based on the predictions, the pharmacokinetic (PK) properties of the drug CS(=O)(=O)c1ccc(Oc2cccc(F)c2)c(S(C)(=O)=O)c1 are as follows:

*   **Oral Bioavailability:** Predicted to be **< 20%**, indicating very poor oral absorption. This suggests that if administered orally, a significant portion of the drug would not reach systemic circulation.
*   **Half-Life:** Predicted to be **1.00 hours** (Obach model). This very short half-life suggests that the drug would be rapidly eliminated from the body, leading to a very brief duration of action.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be **0.00 L/kg** (Lombardo model). This extremely low volume of distribution indicates that the drug has very limited distribution into tissues and is likely largely confined to the plasma or extracellular fluid.

In summary, this drug is predicted to have poor oral bioavailability, a very short half-life, and very limited tissue distribution, suggesting significant challenges for its systemic therapeutic application.
============================================================
SMILES: CS(=O)(=O)c1cccc(C(=O)Nc2ccc(F)cc2C#N)c1
Response: The predicted pharmacokinetic (PK) properties for the drug with the SMILES string CS(=O)(=O)c1cccc(C(=O)Nc2ccc(F)cc2C#N)c1 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%.
*   **Half-Life:** Predicted to be approximately 28.00 hours.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 21.00 L/kg.
============================================================
SMILES: CS(=O)(=O)c1cccc(NC(=O)c2cc(F)cc(C#N)c2)c1
Response: Based on the predictions from the available tools, the pharmacokinetic (PK) properties of the drug CS(=O)(=O)c1cccc(NC(=O)c2cc(F)cc(C#N)c2)c1 are as follows:

*   **Oral Bioavailability:** Predicted to be **< 20%**, indicating poor oral absorption.
*   **Half-Life (Obach model):** Predicted to be **48.00 hours**.
*   **Steady-State Volume of Distribution (VDss, Lombardo method):** Predicted to be **1.00 L/kg**.

Other PK properties, such as specific metabolic pathways (e.g., CYP interactions), plasma protein binding, or detailed clearance mechanisms, could not be assessed with the available tools.
============================================================
SMILES: CS(=O)(=O)c1ccccc1C(=O)Oc1cc(F)cc([N+](=O)[O-])c1
Response: The predicted pharmacokinetic (PK) properties for the drug CS(=O)(=O)c1ccccc1C(=O)Oc1cc(F)cc([N+](=O)[O-])c1 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%.
*   **Half-life (Obach model):** Predicted to be 1.00 hours.
*   **Steady-state Volume of Distribution (VDss Lombardo):** Predicted to be 1.00 L/kg.
============================================================
SMILES: CS(=O)(=O)c1ccccc1CC(=O)Nc1cc(F)cc(C#N)c1
Response: The predicted pharmacokinetic (PK) properties of the drug with SMILES CS(=O)(=O)c1ccccc1CC(=O)Nc1cc(F)cc(C#N)c1 are as follows:

1.  **Oral Bioavailability:** The drug is predicted to have oral bioavailability less than 20%. This suggests that the drug is poorly absorbed when administered orally, which could lead to challenges in achieving therapeutic concentrations via the oral route.
2.  **Half-life:** The predicted half-life is 24.00 hours. A half-life of this duration indicates that the drug persists in the body for a relatively long period, potentially supporting a once-daily dosing regimen.
3.  **Volume of Distribution at Steady State (VDss):** The predicted VDss is 21.00 L/kg. A high VDss value suggests that the drug distributes extensively into tissues outside of the plasma compartment, rather than remaining primarily in the bloodstream. This implies significant tissue penetration and accumulation.

In summary, this drug is predicted to have poor oral absorption, a relatively long systemic half-life, and extensive distribution into body tissues.
============================================================
SMILES: CS(=O)(=O)c1ccccc1NC(=O)c1cc(F)cc2ccoc12
Response: Based on computational predictions from its SMILES structure, the drug CS(=O)(=O)c1ccccc1NC(=O)c1cc(F)cc2ccoc12 exhibits the following pharmacokinetic (PK) properties:

*   **Absorption:** It is predicted to have a low oral bioavailability of less than 20%, suggesting challenges with systemic absorption following oral administration, which could be due to factors like poor solubility, low permeability, or significant first-pass metabolism.
*   **Distribution:** The predicted volume of distribution at steady state (VDss) is 1.00 L/kg, indicating moderate distribution into body tissues.
*   **Elimination:** The predicted half-life is 2.00 hours, suggesting relatively rapid clearance from the body, likely due to quick metabolism or excretion.

Overall, these properties indicate a challenging PK profile for oral drug development, characterized by poor absorption and rapid elimination.
============================================================
SMILES: C[C@@H](C[C@@H](O)c1ccccc1)NC(=O)Nc1cc(F)cc(C#N)c1
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug C[C@@H](C[C@@H](O)c1ccccc1)NC(=O)Nc1cc(F)cc(C#N)c1 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%. This suggests that only a small fraction of the orally administered drug would reach systemic circulation.
*   **Half-Life:** Predicted to be 94.00 hours. This indicates a very long elimination half-life, meaning the drug would persist in the body for an extended period, potentially allowing for less frequent dosing intervals.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 11.00 L/kg. A high VDss value suggests that the drug is extensively distributed into tissues rather than remaining primarily in the bloodstream.
============================================================
SMILES: C[C@H](NC(=O)Nc1cc(F)cc(C#N)c1)[C@@H](O)c1ccccc1
Response: The pharmacokinetic (PK) properties of the drug C[C@H](NC(=O)Nc1cc(F)cc(C#N)c1)[C@@H](O)c1ccccc1 have been predicted as follows:

*   **Oral Bioavailability:** The drug is predicted to have **low oral bioavailability (< 20%)**. This suggests that only a small fraction of an orally administered dose would reach the systemic circulation, indicating potential challenges with oral drug delivery.
*   **Half-Life:** The predicted half-life is **127.00 hours**, which is very long. A long half-life implies that the drug will remain in the body for an extended period, potentially allowing for less frequent dosing but also raising concerns about drug accumulation upon repeated administration and the time required to reach steady-state or eliminate the drug.
*   **Steady-State Volume of Distribution (VDss):** The predicted VDss is **3.00 L/kg**. This value indicates that the drug distributes moderately well into body tissues, beyond just the plasma volume. A VDss of 3.00 L/kg suggests some tissue binding or distribution into total body water.

**Summary of PK Profile:**

This compound is predicted to have poor oral absorption, meaning it would likely not be suitable for oral administration unless absorption enhancers or alternative formulations are considered. If administered via a route that bypasses first-pass metabolism (e.g., intravenously), it would exhibit a very long duration of action due to its prolonged half-life. Its moderate volume of distribution suggests it is not confined strictly to the bloodstream but distributes into tissues to some extent. These properties point towards a drug that would require careful consideration of its administration route and dosing regimen to manage potential accumulation and ensure therapeutic levels are achieved effectively.
============================================================
SMILES: C[C@H](NC(=O)Nc1ccc(C#N)cc1)[C@@H](O)c1cccc(F)c1
Response: The drug with the SMILES `C[C@H](NC(=O)Nc1ccc(C#N)cc1)[C@@H](O)c1cccc(F)c1` has the following predicted pharmacokinetic (PK) properties:

*   **Oral Bioavailability:** Predicted to be less than 20%. This suggests poor absorption from the gastrointestinal tract, which would significantly limit its effectiveness if administered orally.
*   **Half-Life:** Predicted to be 3.00 hours. This indicates a relatively short duration of action, meaning it would likely require frequent dosing to maintain therapeutic concentrations.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 1.00 L/kg. This value suggests that the drug distributes moderately into body tissues, rather than remaining predominantly in the plasma or being highly sequestered in specific tissues.

In summary, the drug is predicted to have low oral bioavailability and a short half-life, suggesting potential challenges for oral administration and the need for frequent dosing if it were to be developed. Its moderate volume of distribution indicates it distributes into body tissues but is not highly sequestered.
============================================================
SMILES: C[C@H](NC(=O)Nc1cccc(C#N)c1)[C@@H](O)c1cccc(F)c1
Response: Based on the analyses performed, the predicted pharmacokinetic (PK) properties for the compound C[C@H](NC(=O)Nc1cccc(C#N)c1)[C@@H](O)c1cccc(F)c1 are:

*   **Oral Bioavailability:** Predicted to be less than 20%, suggesting poor oral absorption.
*   **Half-Life:** Predicted to be approximately 1.00 hour, indicating a relatively short duration of action.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 1.00 L/kg, suggesting a moderate distribution into bodily tissues.

To provide a more complete PK profile, further investigation into plasma protein binding, specific metabolic pathways (e.g., CYP P450 interactions), and clearance mechanisms (renal vs. hepatic) would be necessary.
============================================================
SMILES: C[S@@](=O)C[C@@H](NC(=O)Nc1cc(F)cc(C#N)c1)c1ccccc1
Response: The pharmacokinetic (PK) properties of the drug with SMILES C[S@@](=O)C[C@@H](NC(=O)Nc1cc(F)cc(C#N)c1)c1ccccc1 can be summarized as follows, based on the predictive models:

1.  **Oral Bioavailability:** The predicted oral bioavailability is **less than 20% (<20%)**. This suggests that if administered orally, only a small fraction of the drug would be absorbed into the systemic circulation. This low bioavailability could be due to factors such as poor permeability, extensive first-pass metabolism, or efflux pump activity in the gut. For therapeutic use, this indicates that oral administration might be challenging, potentially requiring high doses, alternative routes of administration, or specialized formulations to achieve effective plasma concentrations.

2.  **Half-life:** The predicted half-life is **13.00 hours**. This indicates a moderate duration of action. A half-life in this range typically allows for once or twice-daily dosing, which is generally favorable for patient adherence in chronic therapies.

3.  **Volume of Distribution at Steady State (VDss):** The predicted VDss is **3.00 L/kg**. This value suggests a moderate to high distribution of the drug from the bloodstream into the peripheral tissues. A VDss significantly greater than the total body water (approximately 0.6 L/kg) implies that the drug is not confined to the plasma but distributes extensively into extravascular compartments, possibly accumulating in certain tissues.

In summary, the drug shows characteristics of relatively poor oral absorption but, once absorbed, it distributes moderately to extensively into tissues and has a half-life conducive to convenient dosing regimens. The low oral bioavailability would be a primary concern for its development as an oral therapeutic agent.
============================================================
SMILES: C[S@](=O)C[C@@H](NC(=O)Nc1cc(F)cc(C#N)c1)c1ccccc1
Response: The predicted pharmacokinetic (PK) properties for the compound with SMILES C[S@](=O)C[C@@H](NC(=O)Nc1cc(F)cc(C#N)c1)c1ccccc1 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%, suggesting poor oral absorption.
*   **Half-Life:** Predicted to be 14.00 hours, indicating a moderate duration of action.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 13.00 L/kg, which suggests extensive distribution into tissues beyond the plasma.
============================================================
SMILES: Cc1cc(C#N)cc(NC(=O)N[C@H](C)[C@H](O)c2cccc(F)c2)c1
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug Cc1cc(C#N)cc(NC(=O)N[C@H](C)[C@H](O)c2cccc(F)c2)c1 are as follows:

*   **Absorption (A):** The predicted oral bioavailability is **less than 20%**, indicating poor oral absorption. This suggests that achieving therapeutic concentrations via oral administration might be challenging, and alternative routes of administration or formulation strategies might be necessary.
*   **Distribution (D):** The predicted steady-state volume of distribution (VDss) is **0.40 L/kg**. This value suggests that the drug is likely distributed primarily within the extracellular fluid and does not extensively partition into tissues or intracellular spaces. A low volume of distribution typically implies limited tissue binding and greater retention within the plasma volume.
*   **Metabolism (M):** While specific enzyme interactions were not directly predicted by a tool, the complex structure with functional groups like an amide bond, a nitrile, and a secondary alcohol suggests potential metabolic pathways. Common pathways for such molecules could include:
    *   **Hydrolysis:** The amide bond (NC(=O)N) could be susceptible to hydrolysis, potentially catalyzed by amidases.
    *   **Oxidation:** The alcohol group (-CH(OH)-) can undergo oxidation, and other parts of the molecule (e.g., aromatic rings, alkyl chains) could be targets for oxidative metabolism, often catalyzed by cytochrome P450 (CYP) enzymes.
    *   **Conjugation:** Metabolites from oxidative or hydrolytic reactions might subsequently undergo conjugation reactions (e.g., glucuronidation, sulfation) to facilitate excretion.
*   **Excretion (E):** The predicted half-life is **1.00 hour**, indicating that the drug is eliminated relatively quickly from the body. A short half-life often necessitates more frequent dosing to maintain therapeutic concentrations. The exact route of excretion (renal, biliary) would depend on the nature of the parent drug and its metabolites (e.g., polarity, molecular weight).

In summary, this drug is predicted to have poor oral bioavailability, a relatively small volume of distribution, and a rapid elimination half-life. Its metabolism is likely to involve hydrolysis and/or oxidative pathways.
============================================================
SMILES: Cc1ccc(C#N)cc1NC(=O)N[C@H]1C[C@H]1c1cccc(F)c1
Response: Based on the *in silico* predictions performed, the pharmacokinetic (PK) properties of the drug Cc1ccc(C#N)cc1NC(=O)N[C@H]1C[C@H]1c1cccc(F)c1 are as follows:

1.  **Oral Bioavailability:** The drug is predicted to have **low oral bioavailability (< 20%)**. This suggests that only a small fraction of the orally administered dose reaches the systemic circulation, likely due to poor absorption, significant first-pass metabolism, or efflux by transporters in the gut.
2.  **Half-Life:** The predicted half-life is **2.00 hours**. This indicates a relatively rapid elimination from the body, meaning the drug concentration in plasma will decrease by half every two hours.
3.  **Volume of Distribution at Steady State (VDss):** The predicted VDss is **1.00 L/kg**. This value suggests that the drug distributes moderately into tissues beyond the plasma compartment, but it does not appear to be extensively sequestered in peripheral tissues.

These properties collectively describe the drug's disposition in the body, indicating challenges for oral administration due to low absorption and a need for frequent dosing due to rapid elimination.
============================================================
SMILES: Cc1ccc(C(=O)Nc2ccccc2S(C)(=O)=O)cc1C#N
Response: The pharmacokinetic (PK) properties of the drug with the SMILES Cc1ccc(C(=O)Nc2ccccc2S(C)(=O)=O)cc1C#N are predicted as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%.
*   **Half-life (Obach model):** Predicted to be 1.00 hours.
*   **Steady-state Volume of Distribution (VDss, Lombardo method):** Predicted to be 1.00 L/kg.
============================================================
SMILES: Cc1ccc([C@H](O)[C@H](C)NC(=O)Nc2cc(F)cc(C#N)c2)cc1
Response: The pharmacokinetic (PK) properties of the drug Cc1ccc([C@H](O)[C@H](C)NC(=O)Nc2cc(F)cc(C#N)c2)cc1, based on the available predictions, are as follows:

*   **Absorption (Bioavailability):** The drug is predicted to have low oral bioavailability, estimated to be less than 20%. This suggests that only a small fraction of the orally administered dose would reach systemic circulation.
*   **Distribution (Volume of Distribution at Steady State, VDss):** The predicted volume of distribution at steady state (VDss) is 13.00 L/kg. A high VDss value (typically > 1 L/kg) generally indicates extensive distribution of the drug into tissues outside the plasma.
*   **Elimination (Half-Life):** The predicted half-life of the drug is 14.00 hours. This suggests that the drug would be eliminated from the body at a moderate rate, requiring dosing typically once or twice daily to maintain therapeutic concentrations.
============================================================
SMILES: N#Cc1cc(F)cc(NC(=O)c2ccccc2Oc2ccccc2)c1
Response: Based on the computational predictions, the pharmacokinetic (PK) properties for the drug N#Cc1cc(F)cc(NC(=O)c2ccccc2Oc2ccccc2)c1 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%, suggesting poor oral absorption.
*   **Half-Life:** Predicted to be 300.00 hours (based on the Obach model), indicating a very long duration of action.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 1.00 L/kg (based on the Lombardo model), which suggests moderate distribution into tissues.
============================================================
SMILES: N#Cc1cc(F)cc(OCc2nnnn2Cc2ccccc2)c1
Response: The predicted pharmacokinetic (PK) properties for the drug N#Cc1cc(F)cc(OCc2nnnn2Cc2ccccc2)c1 are as follows:

*   **Oral Bioavailability:** Predicted to be low, specifically less than 20%. This suggests that only a small fraction of the orally administered drug would reach systemic circulation.
*   **Half-Life:** Predicted to be 3.00 hours (based on the Obach model). This indicates a relatively short duration of action, meaning the drug would be eliminated from the body fairly quickly.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 1.00 L/kg (based on the Lombardo model). This value suggests that the drug is moderately distributed into tissues, with a volume of distribution close to the body water volume.
============================================================
SMILES: N#Cc1cc(F)cc(Oc2ccc(S(=O)(=O)C(F)F)c3c2CC(F)(F)[C@@H]3O)c1
Response: Based on the cheminformatics predictions for the drug N#Cc1cc(F)cc(Oc2ccc(S(=O)(=O)C(F)F)c3c2CC(F)(F)[C@@H]3O)c1, its pharmacokinetic (PK) properties are as follows:

*   **Oral Bioavailability:** Predicted to be **< 20%**. This indicates poor oral absorption, meaning that if the drug were administered orally, a substantial portion would not reach systemic circulation. This could necessitate higher doses or the exploration of alternative routes of administration to achieve therapeutic concentrations.
*   **Half-life:** Predicted to be **2.1 hours**. This is a relatively short half-life, suggesting that the drug is eliminated from the body quite rapidly. To maintain sustained therapeutic levels, frequent dosing would likely be required.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be **0.8 L/kg**. This value suggests a moderate volume of distribution, implying that the drug distributes somewhat beyond the plasma volume into tissues, but it is not extensively distributed throughout the body's total water.
============================================================
SMILES: N#Cc1cc(F)cc(Oc2ccc(S(=O)(=O)C(F)F)c3c2CC(F)(F)[C@H]3O)c1
Response: Based on the *in silico* predictions, the pharmacokinetic (PK) properties of the drug N#Cc1cc(F)cc(Oc2ccc(S(=O)(=O)C(F)F)c3c2CC(F)(F)[C@H]3O)c1 are as follows:

*   **Absorption:** It is predicted to have **low oral bioavailability (< 20%)**, suggesting that a significant portion of the drug may not be absorbed into the systemic circulation when administered orally.
*   **Distribution:** The predicted **volume of distribution at steady state (VDss) is 1.00 L/kg**, which suggests that the drug is relatively well-distributed throughout the body, but not extensively accumulated in tissues.
*   **Elimination (Half-life):** The predicted **half-life is 2.00 hours**, indicating a relatively rapid elimination from the body. This short half-life means the drug would likely need frequent dosing to maintain therapeutic concentrations.

Further *in silico* or experimental investigations would be crucial to fully characterize its metabolism (e.g., major metabolic pathways, involvement of CYP enzymes) and excretion routes (e.g., renal, biliary) to provide a complete ADME profile.
============================================================
SMILES: N#Cc1cc(F)cc(Oc2ccc(S(=O)(=O)CF)c3c2CC(F)(F)[C@H]3O)c1
Response: The predicted pharmacokinetic (PK) properties of the drug N#Cc1cc(F)cc(Oc2ccc(S(=O)(=O)CF)c3c2CC(F)(F)[C@H]3O)c1 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%, indicating poor absorption when administered orally.
*   **Half-life (Obach model):** Predicted to be approximately 1.00 hour, suggesting that the compound is rapidly eliminated from the body.
*   **Steady-state Volume of Distribution (VDss Lombardo model):** Predicted to be 1.00 L/kg, which suggests moderate distribution into body tissues.

In summary, this drug is predicted to have low oral bioavailability and a short half-life, pointing towards rapid clearance. Its moderate volume of distribution suggests it is not extensively sequestered in tissues.
============================================================
SMILES: N#Cc1cc(F)cc(Oc2ccc3c(c2C(F)F)C(=O)CS3(=O)=O)c1
Response: The pharmacokinetic (PK) properties of the drug with the SMILES string N#Cc1cc(F)cc(Oc2ccc3c(c2C(F)F)C(=O)CS3(=O)=O)c1 are predicted as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%.
*   **Half-Life:** Approximately 1.00 hour (based on the Obach model).
*   **Steady-State Volume of Distribution (VDss):** Approximately 1.00 L/kg (based on the Lombardo model).
============================================================
SMILES: N#Cc1cc(F)ccc1CS(=O)(=O)N[C@@H]1CCCC12CCOCC2
Response: The PK properties of the drug N#Cc1cc(F)ccc1CS(=O)(=O)N[C@@H]1CCCC12CCOCC2 are as follows:

*   **Oral Bioavailability:** Predicted to be low, specifically less than 20%. This suggests that only a small fraction of the administered dose would reach systemic circulation when taken orally.
*   **Half-life:** Predicted to be approximately 4.00 hours. This indicates how long it takes for the concentration of the drug in the body to reduce by half. A half-life of 4 hours suggests the drug is eliminated relatively quickly from the body.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 0.00 L/kg. This value is extremely low and suggests that the drug is largely confined to the plasma compartment and does not distribute significantly into tissues. This might be indicative of high plasma protein binding or poor tissue permeability.
============================================================
SMILES: N#Cc1cc(O)cc(C(=O)Nc2ccccc2Oc2cccc(F)c2)c1
Response: Based on the predictions, the pharmacokinetic properties of the drug N#Cc1cc(O)cc(C(=O)Nc2ccccc2Oc2cccc(F)c2)c1 are as follows:

*   **Oral Bioavailability:** The drug is predicted to have poor oral bioavailability, specifically **less than 20%**. This suggests that a significant portion of the drug may not be absorbed into the systemic circulation if administered orally.
*   **Half-life:** The predicted half-life of the drug is **62.00 hours**. This indicates a long duration of action, meaning the drug will remain in the body for an extended period, which could allow for less frequent dosing.
*   **Volume of Distribution at Steady State (VDss):** The predicted VDss is **7.00 L/kg**. This high value suggests extensive distribution of the drug from the bloodstream into various tissues and organs throughout the body, indicating it is not primarily confined to the plasma.
============================================================
SMILES: N#Cc1ccc(C(=O)Nc2cc(F)ccc2Oc2ccccc2)cc1
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug with SMILES N#Cc1ccc(C(=O)Nc2cc(F)ccc2Oc2ccccc2)cc1 are as follows:

1.  **Oral Bioavailability:** The drug is predicted to have **oral bioavailability < 20%**.
    *   **Implication:** This indicates very poor absorption from the gastrointestinal tract into the systemic circulation. A significant portion of the administered oral dose would not reach the bloodstream, potentially leading to insufficient therapeutic concentrations or requiring very high doses, which might exacerbate local gastrointestinal side effects. This suggests that the oral route might not be the most suitable or efficient route of administration for this compound.

2.  **Half-life:** The drug is predicted to have an exceptionally long half-life of **1821.00 hours** (approximately 75.8 days).
    *   **Implication:** An extremely long half-life means the drug is eliminated very slowly from the body. This can lead to significant accumulation in the body with repeated dosing, increasing the risk of systemic toxicity. Reaching steady-state concentrations would take a very long time, and the drug would persist in the body for an extended period even after discontinuation of therapy, making dose adjustments or management of adverse effects challenging.

3.  **Volume of Distribution at Steady State (VDss):** The drug has a predicted VDss of **97.00 L/kg**.
    *   **Implication:** This is a very high volume of distribution, indicating that the drug widely distributes from the bloodstream into body tissues and compartments outside the plasma. A high VDss suggests that the drug is highly lipophilic and/or binds extensively to tissue components. This extensive tissue distribution contributes to its very long half-life, as the drug is slow to return to the central compartment for elimination.

**Overall PK Profile and Implications:**

The combination of very poor oral bioavailability, an extremely long half-life, and a very high volume of distribution paints a challenging PK profile for this compound.

*   **Limited Systemic Exposure:** The low oral bioavailability suggests that achieving effective systemic concentrations via oral administration would be difficult.
*   **High Risk of Accumulation and Toxicity:** The exceptionally long half-life coupled with extensive tissue distribution (high VDss) indicates a strong propensity for drug accumulation in the body and tissues with repeated dosing, raising significant concerns about potential chronic toxicity.
*   **Dosing Regimen Challenges:** Designing an appropriate dosing regimen would be complex. High initial loading doses might be needed to achieve therapeutic levels quickly, but subsequent maintenance doses would need to be very carefully managed and infrequent to avoid excessive accumulation. The slow clearance would make reversal of adverse effects or achieving dose adjustments very difficult.
*   **Potential for Off-target Effects:** Extensive tissue distribution might also increase the likelihood of the drug interacting with unintended targets in various tissues, leading to off-target adverse effects.

In summary, while computational predictions are preliminary, these PK properties suggest that this compound would face significant hurdles in drug development, particularly regarding safe and effective dosing, and managing potential long-term toxicity due to its extreme persistence in the body.
============================================================
SMILES: N#Cc1ccc(C(=O)Nc2ccccc2Oc2cccc(F)c2)cc1
Response: Based on the predictions performed, the PK properties of the drug N#Cc1ccc(C(=O)Nc2ccccc2Oc2cccc(F)c2)cc1 are as follows:

*   **Oral Bioavailability:** The drug is predicted to have low oral bioavailability, specifically less than 20%.
*   **Half-Life:** The predicted half-life of the drug is very long, estimated at 2821.00 hours (approximately 117.5 days).
*   **Steady-State Volume of Distribution (VDss):** The predicted steady-state volume of distribution is 9.00 L/kg.
============================================================
SMILES: N#Cc1ccc(F)c(C(=O)Nc2cc(F)ccc2Oc2ccccc2)c1
Response: The PK properties of the drug N#Cc1ccc(F)c(C(=O)Nc2cc(F)ccc2Oc2ccccc2)c1 are as follows:

*   **Absorption:**
    *   Oral bioavailability is predicted to be **< 20%**, indicating poor oral absorption.
    *   Caco-2 permeability is predicted to be **< 4 (cm/s x 10^-6)**, suggesting low intestinal permeability.
*   **Distribution:**
    *   The LogP value is **5.8**, indicating high lipophilicity, which may lead to extensive tissue distribution.
    *   The TPSA (Topological Polar Surface Area) is **69.1 Å²**.
    *   The steady-state volume of distribution (VDss) is predicted to be **71.00 L/kg**, which is a high value, consistent with high lipophilicity and likely extensive distribution into tissues.
*   **Metabolism:**
    *   The drug is predicted to be a **weak inhibitor of CYP2C9 and CYP3A4**, suggesting a potential for drug-drug interactions if co-administered with substrates of these enzymes.
    *   It is predicted to be a **substrate for CYP2D6**, indicating that it is likely metabolized by this enzyme.
*   **Elimination:**
    *   The predicted half-life (Obach model) is **72.00 hours**, suggesting a very long duration of action.
============================================================
SMILES: N#Cc1ccc(OC(=O)C(c2ccccc2)c2ccccc2)c(F)c1
Response: The PK properties of the drug N#Cc1ccc(OC(=O)C(c2ccccc2)c2ccccc2)c(F)c1 are predicted as follows:

*   **Oral Bioavailability:** Less than 20%, indicating poor oral absorption. This suggests that if administered orally, a significant portion of the dose would not reach the systemic circulation.
*   **Half-life (Obach model):** 721.00 hours, which is an exceptionally long half-life. This implies that the drug would remain in the body for a very prolonged period, potentially leading to slow elimination and accumulation if dosed repeatedly.
*   **Steady-state Volume of Distribution (VDss Lombardo model):** 0.00 L/kg. This extremely low predicted volume of distribution suggests that the drug largely remains within the vascular compartment and has very limited distribution into tissues. Such a low VDss could indicate high plasma protein binding or that the molecule is effectively excluded from tissue compartments.
============================================================
SMILES: N#Cc1cccc(C(=O)Nc2cc(F)ccc2Oc2ccccc2)c1
Response: Based on the analyses performed, the predicted pharmacokinetic (PK) properties of the drug N#Cc1cccc(C(=O)Nc2cc(F)ccc2Oc2ccccc2)c1 are as follows:

*   **Oral Bioavailability:** The drug is predicted to have oral bioavailability of less than 20%, indicating poor absorption when administered orally. This suggests that alternative routes of administration or formulation strategies might be necessary for achieving therapeutic concentrations.
*   **Half-life:** The predicted half-life is 1.00 hour. This very short half-life suggests that the drug would be rapidly eliminated from the body, potentially requiring frequent dosing to maintain therapeutic levels.
*   **Volume of Distribution at Steady State (VDss):** The predicted VDss is 1.00 L/kg. This value suggests that the drug exhibits moderate distribution into tissues, rather than being largely confined to the plasma compartment or extensively distributed throughout the body's total water.

In summary, this drug is characterized by **poor oral absorption**, a **very short duration of action**, and **moderate tissue distribution**. Further investigation into its solubility, permeability, plasma protein binding, specific metabolic pathways (e.g., CYP interactions), and excretion routes would be necessary to provide a more complete pharmacokinetic profile.
============================================================
